Nivolumab �li�kili Trakea�zefagial Fist�l

Bahad�r, Ay�e; Yurt, Sibel; �zg�l, Mehmet Akif; Karag�l, Muhammet At�f; Arafat, Levent

Cilt : 13 Say� : 3 Y�l : 2024

13/3Son Say� Erken Bask� Ar�iv Pop�ler Makaleler

Yay�n Hakk� Devir Formu

Yazar Katk� Formu

H�zl� Arama

Nivolumab �li�kili Trakea�zefagial Fist�l [Respir Case Rep]

Respir Case Rep. 2022; 11(3): 119-122 | DOI: 10.5505/respircase.2022.70846

Nivolumab �li�kili Trakea�zefagial Fist�l

Ay�e Bahad�r, Sibel Yurt, Mehmet Akif �zg�l, Muhammet At�f Karag�l, Levent Arafat
�am ve Sakura �ehir Hastanesi, �stanbul

Trakea ve �zafagus aras�nda patolojik bir ba�lant� olmas� trakea-�zafagiyal fist�l (T�F) olarak adland�r�l�r, do�u�tan veya bening ya da maling nedenlere ba�l� sonradan olu�abilmektedir. T�F, akci�er ve �zefagus kanserlerinde kemoradyoterapi sonras� veya mediastinal invazyon nedeni ile geli�en, y�ksek morbidite ve mortaliteye neden olan bir komplikasyondur. Son y�llarda Non-small cell akci�er kanseri (NSCLC) tedavisinde immun kontrol inhibit�r (ICI) ila�lar�n kullan�m�n�n art��na ba�l� nadir g�r�len yan etkiler ortaya ��kmakta ve olgu baz�nda bildirilmektedir. Yetmi� sekiz ya��nda bir y�l �nce NSCLC tans� ile sol pn�monektomi olan olgumuzda mediastene invaze kitlenin �zafagusa bas�s�na ba�l� disfaji nedeni ile iki ay �nce �zafagusa stent uygulama ve nivolumab kullan�m �yk�s� vard�. Yat��n�n ilk haftas�nda hastada T�F geli�ti. Trakeaya stent yerle�tirilmesi d��n�len olgumuz, masif hemoptizi geli�mesi nedeni ile eksitus oldu. Ay�r�c� tan� sonras� ICI ila�a ba�l� yan etki olarak T�F geli�ti�i d��n�ld�. Nadir bir yan etki olarak g�r�lmesi nedeni ile olgumuzu literat�r bilgileri ile sunmak istedik.

Anahtar Kelimeler: Trakea�zefagial fist�l, akci�er kanseri, immunoterapi

Tracheoesophageal Fistula Associated with Nivolumab

Ay�e Bahad�r, Sibel Yurt, Mehmet Akif �zg�l, Muhammet At�f Karag�l, Levent Arafat
�am ve Sakura City Hospital, �stanbul, T�rkiye

Tracheoesophageal fistula (TEF) is a pathological connection between the trachea and the esophagus that can be congenital or can develop in older ages as a result of benign or malignant causes. It develops as a result of mediastinal invasion or after chemoradiotherapy in lung and esophageal cancers, and is associated with high mortality and morbidity. TEF has been reported in the past to be a rare side effect of immune control inhibitor (ICI) drugs used for the treatment of non-small cell lung cancer, and several cases have been reported. A 78-year-old patient who underwent a left pneumonectomy after being diagnosed with NSCLC one year earlier had a history of esophageal stenting and Nivolumab use two months previously to relieve the pressure of a mediastinum mass invading the esophagus that was causing dysphagia in the patient. The patient developed TEF in the first week of hospitalization, which was thought to be a side effect of the ICI drugs. Our case, who was thought to place a stent in the trachea, died after developing massive hemoptysis. We present this case of the development of TEF to literature due to its rarity as a side effect of ICI drugs.

Keywords: Tracheoesophageal fistula, lung cancer, immunotherapy

Sorumlu Yazar: Ay�e Bahad�r, T�rkiye
Makale Dili: �ngilizce

ATIF KOPYALA

Tam Metin PDF At�f dosyas� indir RIS EndNote BibTex Medlars Procite Reference Manager Yazara e-posta g�nder Benzer makaleler PubMed Google Scholar